Jordi Mata-Fink, Gate Bioscience CEO

‘Small mol­e­cules are sexy again’: Gate Bio­science de­buts with $60M and a new way to stop dis­ease-caus­ing pro­teins

Gate Bio­science has raised $60 mil­lion to de­vel­op a new type of pill-based med­i­cine — which it calls a mol­e­c­u­lar gate — that can go af­ter the spec­trum of ma­li­cious pro­teins.

The Bris­bane, CA biotech was start­ed in 2021 by Jor­di Ma­ta‐Fink, a mem­ber of the found­ing team for Gen­er­ate:Bio­med­i­cines and now Gate’s CEO; Pat Sharp, whose post­doc work serves as the foun­da­tion for the com­pa­ny’s plat­form; and Ra­man Tal­war, a for­mer se­nior as­so­ciate at Flag­ship Pi­o­neer­ing. The Se­ries A round was led by Ver­sant Ven­tures and An­dreessen Horowitz (a16z), and in­vestors al­so in­clud­ed ARCH Ven­ture Part­ners and GV, Google’s ven­ture arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.